FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502869-17-01

Acronym

FusionVAC22_01

Enrollment

Registered

2023-08-29

Start date

2023-09-26

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fibrolamellar hepatocellular carcinoma, tumor entities carrying the oncogenic driver fusion DNAJB1-PRKACA

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 6, 2026